BridgeBio Pharma Inc (NASDAQ: BBIO) is 46.03% higher on its value in year-to-date trading and has touched a low of $21.62 and a high of $41.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BBIO stock was last observed hovering at around $41.14 in the last trading session, with the day’s loss setting it -1.07%.
Currently trading at $40.07, the stock is 9.39% and 12.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.68 million and changing -2.60% at the moment leaves the stock 29.59% off its SMA200. BBIO registered 38.17% gain for a year compared to 6-month gain of 44.81%.
The stock witnessed a 18.41% loss in the last 1 month and extending the period to 3 months gives it a 24.48%, and is -0.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.52% over the week and 2.31% over the month.
BridgeBio Pharma Inc (BBIO) has around 730 employees, a market worth around $7.61B and $127.42M in sales. Profit margin for the company is -524.25%. Distance from 52-week low is 85.34% and -3.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-95.16%).
The EPS is expected to shrink by -2.22% this year.
BridgeBio Pharma Inc (BBIO) Top Institutional Holders
The shares outstanding are 189.83M, and float is at 160.74M with Short Float at 13.68%.
The top institutional shareholder in the company is KOHLBERG KRAVIS ROBERTS & CO. L.P. with over 31.06 million shares valued at $786.77 million. The investor’s holdings represent 16.5582% of the BBIO Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 25.12 million shares valued at $636.31 million to account for 13.3917 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 14.05 million shares representing 7.4924% and valued at over $356.01 million, while BLACKROCK INC. holds 6.636 of the shares totaling 12.45 million with a market value of $315.31 million.
BridgeBio Pharma Inc (BBIO) Insider Activity
The most recent transaction is an insider sale by Valantine Hannah, the company’s Director. SEC filings show that Valantine Hannah sold 4,292 shares of the company’s common stock on Jun 10 ’25 at a price of $40.00 per share for a total of $0.17 million. Following the sale, the insider now owns 1764.0 shares.
Still, SEC filings show that on May 20 ’25, Kumar Neil (Chief Executive Officer) disposed off 75,000 shares at an average price of $33.40 for $2.5 million. The insider now directly holds 4,798,447 shares of BridgeBio Pharma Inc (BBIO).
